PhD Scholarship in Oxytocinergic Signaling: This PhD project aims to explore the role of the neuropeptide oxytocin (OT) in suppressing tumor growth in lung, breast, and pancreatic cancers. Through a combination of molecular assessments and animal models, the research seeks to understand how OT influences tumor progression and assess its potential as an adjunctive therapy in cancer treatment.
PhD Scholarship in Stimulation of Oxytocinergic Signaling to Suppress Extracranial Tumor Growth
Designation
PhD Candidate
Research Area
Cancer Biology, Molecular Biology, Pharmacology
Location
Heidelberg, Germany
Eligibility/Qualification
- Master’s degree in Cancer Biology or related fields
- Proficiency in cell culture techniques
- Experience with immunohistochemistry, confocal imaging, and -omics data analysis
- Prior experience with animal models is preferred (FELASA B certificate or equivalent)
- Strong communication and organizational skills
Description
The successful candidate will engage in a multidisciplinary approach to investigate the effects of oxytocin and its receptors on various extracranial tumors. Key objectives include:
- Utilizing specific oxytocin receptor agonists and antagonists in mouse models.
- Co-applying oxytocin with existing cancer therapeutics to evaluate enhanced efficacy.
- Monitoring tumor growth, survival rates, and conducting molecular assessments post-treatment.
- Performing complementary studies in cancer cell lines to identify intracellular signaling pathways modulated by oxytocin.
How to Apply
Interested candidates should submit their application materials, including a CV, cover letter, and contact details for references, via the designated application portal linked on the university’s career page.
Last Date for Apply
Applications are accepted from 26 November 2024 until 31 December 2024.
